The purpose of the study is to determine whether Brenipatide can improve lung function compared with placebo in adults with COPD. Lung function is mainly assessed by measuring the change from the start of the trial in the amount of air a person can force out of the lungs in one second, known as Forced Expiratory Volume in 1 Second (FEV1). This measurement helps to understand how well the lungs are working.

Participants will be randomly assigned to receive either the study drug or placebo for approximately one year, with regular clinic visits to receive the injection, monitor health, and check for any side effects. Throughout the study, safety checks and simple breathing tests will be performed to gather information on how the treatment affects the disease.

Participants first go through a short titration phase, during which the study medication dose is slowly increased to the target amount to help the body adjust. After reaching the target dose, a maintenance period of up to sixteen weeks follows, during which the dose remains steady and seizure activity is recorded. The study is randomized, double‑blind, and placebo‑controlled, meaning that assignment to fluoxetine or placebo is random and neither the participants nor the investigators know which one is being taken.

In addition to counting seizures, the study monitors side effects, measures fluoxetine levels in the blood, and evaluates changes in behavior using a standardized child behavior checklist, which is a questionnaire completed by caregivers to assess mood and conduct. Any increase in seizure severity or appearance of new seizure types is also documented, and all observations are used to assess the overall safety and effectiveness of the treatment.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff will know which treatment is being given (double‑blind). This is a phase 2 trial, meaning it is an early test of how well the drug works and how safe it is. After taking the tablets daily, subjects will attend a few clinic visits over about four months, during which doctors will count the facial lesions and evaluate overall skin appearance using a simple grading system. Any side effects that arise will be recorded throughout the study period.

The purpose of the trial is to determine whether survodutide can lower the risk of serious liver‑related events and death in people with compensated cirrhosis due to NASH/MASH. Participants will receive the study injection each week for about a year and will attend regular clinic visits for safety checks, blood tests, and imaging. The main outcome looks at the time until the first occurrence of any major event such as liver transplant, death, hepatic decompensation (a worsening of liver function), a rise in the MELD score (a number that reflects how well the liver works) to 15 or higher, or the development of CSPH (high blood pressure in the vessels of the liver). Additional measurements include changes in the ELF score (a blood test that indicates liver scarring), body weight, blood sugar levels, and liver stiffness assessed by FibroScan (an ultrasound that measures how firm the liver is) and MRE (a type of MRI scan for the same purpose). Blood tests will also track liver enzymes AST and ALT, which rise when liver cells are damaged.

The purpose of the study is to find out if Brenipatide can help reduce severe asthma attacks compared to placebo. A severe asthma attack, also called an exacerbation, is when asthma symptoms suddenly get much worse and may require treatment with oral steroids or even a hospital visit. The study will measure how many severe asthma attacks happen over the course of the treatment period.

The study will last for 52 weeks, which is about one year. People taking part will be randomly assigned to receive either Brenipatide or placebo, and neither they nor their doctors will know which treatment they are getting during the study. Throughout the study, doctors will monitor how well the treatment works and check for any side effects. To join this study, people must have been diagnosed with asthma and have been taking asthma controller medication for at least 12 months, and they must have had at least one severe asthma attack that required oral steroid treatment in the past year.

The purpose of the trial is to see whether the combination with ivonescimab can keep the disease from getting worse longer than the combination with bevacizumab. Participants are randomly placed into one of the two groups, receive the assigned medicines by IV every two weeks for several cycles, and attend regular clinic visits for monitoring and safety checks.

The main outcome being watched is Progression-Free Survival, which means the length of time the cancer does not grow or spread. Additional observations include side effects, overall health, and quality of life, which are recorded throughout the treatment and follow‑up period.

The purpose of the study is to find out if felzartamab works better than placebo in treating this type of inflammation in transplanted kidneys. The study will also look at whether the medication is safe and how it affects kidney function over time. The inflammation is identified through a kidney biopsy, which is a procedure where a small piece of kidney tissue is examined under a microscope. The study will check if the medication can reduce or eliminate the inflammation seen in the biopsy and whether it can help maintain or improve how well the transplanted kidney is working.

The study is divided into different parts and will last for about one year for each participant. During this time, participants will receive the study medication or placebo through infusions at scheduled visits. Throughout the study, participants will have regular check-ups that include blood tests, urine tests, measurements of vital signs like blood pressure and heart rate, and tests to check how well the kidney is functioning. Another kidney biopsy will be performed during the study to see if there are any changes in the inflammation. The study will also monitor for any side effects or unwanted reactions to the medication.

The purpose of the study is to evaluate how effective Felzartamab is in treating patients with active or chronic active AMR. Participants in the study will receive either Felzartamab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 12 months, during which participants will have regular visits to monitor their health and the effects of the treatment.

In addition to Felzartamab, the study will also use a Saline Solution for infusion, which is a simple saltwater solution often used in medical treatments. The study aims to gather information on the safety and effectiveness of Felzartamab in improving the condition of kidney transplant recipients experiencing AMR. Participants will be closely monitored throughout the study to ensure their well-being and to collect data on how the treatment affects their condition.

The aim is to describe how different patients experience the disease, how well their symptoms are controlled, and how the medicine and other treatments are used over time. Participants will be asked to attend regular visits where information about their health, use of inhalers, and any flare‑ups will be recorded, and simple breathing tests will be done to check changes in lung function. Blood or breath samples will also be collected to measure biomarkers that indicate the level of airway inflammation.

Over the study period, people will complete questionnaires about daily activities, sleep, and how asthma affects work or school, and doctors will note any visits to emergency services or hospitals. The collected data will help understand the relationship between the measured inflammation markers and the way symptoms change, without requiring any experimental procedures beyond routine care.

The purpose is to determine whether the monthly treatment can achieve greater weight loss than the placebo over a period of about 72 weeks. Participants are randomly assigned to receive either the medication at one of several dose levels or the placebo, and neither the participants nor the study staff know which is administered. Injections are given every four weeks, and participants attend regular clinic visits where their weight, waist size, blood pressure, and physical function are measured.

During the study, participants have regular check‑ups that include blood tests, a scan called MRI (which creates detailed pictures of internal organs) to measure spleen and liver size, and assessments of blood‑carrying protein (hemoglobin) and tiny blood‑clotting cells (platelet count). A questionnaire that looks at everyday skills and motor abilities is also completed. Blood samples are taken to measure substances that indicate disease activity, and any side effects or safety concerns are recorded throughout the study period.

The purpose of the study is to find out if the under‑skin injection works at least as well as the vein infusion in terms of how the drug moves through the body (pharmacokinetic). Participants are randomly assigned to one of the two ways of receiving the medicine and will visit the clinic regularly for blood tests, imaging scans to see the tumor, and safety checks. The trial lasts for several months, during which any side effects are recorded and managed.

The purpose of the study is to determine whether weekly injections of the drug improve nerve symptoms compared with the placebo. Participants will receive an injection each week for several months and will attend regular visits where doctors will check nerve function using a questionnaire called the mTCNS (a score that rates how severe the nerve problems are). Other questionnaires will also be used, such as the Norfolk QoL-DN (a quality‑of‑life survey for nerve disease), the clinESSDAI and ESSDAI (measures of overall disease activity), the NPQ (a questionnaire about pain), a NRS rating for difficulty thinking, and patient‑ and clinician‑rated impression scales (PGIS, PGIC, CGIS, and CGI). Fatigue will be measured with the FACIT-Fatigue questionnaire.

Throughout the study, safety will be monitored by checking vital signs, heart rhythm, blood tests, and any side effects that may occur. Participants will have the opportunity to report any adverse events, and the study team will evaluate the seriousness of any findings. The overall design allows comparison of the drug’s effect with the placebo while keeping participants and investigators unaware of which treatment is being given.

The purpose of the study is to see whether a coordinated care team made up of an oncologist, a geriatric doctor, a pharmacist and a pharmacologist can lower the number of serious side effects compared with usual care. Participants will start their oral medication and then have regular visits with the care team for up to two years. At each visit doctors will look for side effects, do blood tests, and ask about any problems that affect the blood (hematologic) or other parts of the body (non‑hematologic). A “grade ≥ 3” side effect means it is strong enough to need medical help, and a “grade ≥ 4” blood problem is very serious. The study also records any hospital stays, overall health, and quality‑of‑life questionnaires, while the pharmacist reviews all medicines to avoid unsafe combinations.

The main goal is to see if the drug can bring the level of cortisol measured in urine back to normal. The trial is double‑blind, meaning neither the participants nor the doctors know who gets the real medicine, and it lasts about 30 weeks. People are randomly assigned to one of the two groups and take a tablet each day.

During the study, participants will provide urine samples to measure urinary‑free cortisol, have their blood pressure checked regularly, and may undergo a sugar‑drink test (OGTT) to look at how their body handles glucose. These checks help researchers understand how well the treatment works and whether any side effects appear. The study involves several clinic visits, simple tests, and daily medication taken at home.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

The purpose of the study is to find out which heparin dose best prevents tiny areas of reduced blood flow in the brain that are not felt as symptoms but can be seen on a brain scan called diffusion-weighted imaging (a type of MRI) performed about a day after the procedure. Participants are randomly assigned to one of the two dose groups, receive the medication during the embolization, stay in the hospital for monitoring, and have a brain scan 24 ± 12 hours later to check for these silent lesions, as well as to watch for any bleeding or stroke that might occur shortly after the treatment.

Participants will receive an intravenous infusion of a new medicine called Imzokitug together with Pumitamig and a chemotherapy regimen known as Platinum-Doublet Chemotherapy. The chemotherapy uses two platinum‑based drugs that work by damaging the DNA of cancer cells, making it harder for them to grow. In the comparison group, patients will receive only Pumitamig and the same chemotherapy without the experimental drug. All medicines are given through a vein, usually every few weeks, and doctors will watch for side effects such as nausea, fatigue, or changes in blood counts.

The purpose of the trial is to see whether adding the experimental drug improves the proportion of patients whose tumors shrink or disappear, a measure called the objective response rate. Throughout the study, doctors will measure tumor size with imaging scans and evaluate the changes using criteria called RECIST, which provide a standard way to decide if a tumor has gotten smaller, stayed the same, or grown. Participants will be followed for several months after treatment to track how long any tumor shrinkage lasts, how long they stay without disease worsening, and overall survival, while safety is continually monitored.

The purpose of the study is to evaluate the safety, tolerability, and effect of the medication on the activity of a clot‑helping protein known as Factor XI after eight weeks. Participants will receive a few injections over several weeks and will attend brief visits for simple check‑ups, including blood tests and basic heart monitoring, to track any side effects and how the drug behaves in the body.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Durvalumab and are still benefiting from it, according to their doctor. The study will monitor the safety and how well patients tolerate the treatment. In addition to Durvalumab, the study may also involve other medications such as Infliximab and Mycophenolate Mofetil, which are used for different purposes. Infliximab is administered through an infusion, while Mycophenolate Mofetil is taken orally in capsule form.

Participants in this study will continue to receive their treatment as long as they are benefiting from it. The study will keep track of any serious side effects that occur up to 90 days after the last dose of the study treatment. This trial aims to ensure that patients who are doing well on their current treatment can continue to receive it safely.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The purpose of the trial is to determine how well this combination can shrink or control the disease. Participants receive the injection of epcoritamab and the pill of lenalidomide over several treatment cycles, with regular visits to check health, monitor the cancer’s response, and watch for any side effects. After the treatment period, patients continue to be followed to see how long any benefit lasts and to ensure safety.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the study is to compare how these medicines change the brain’s ability to reorganize (known as cortical plasticity) and the capacity to learn new motor tasks during the early recovery period after a stroke. Cortical plasticity refers to the brain’s natural ability to form new connections and adapt after injury, and motor learning describes how well a person can acquire and retain new movement skills.

Participants will undergo a series of short visits in which brain activity is measured, a simple learning task is performed, and the assigned medication is taken for a set period. Measurements are taken before the medication starts and after each treatment phase, allowing researchers to see any changes over time while safety is continuously checked.

The purpose of the study is to determine the highest dose that can be given safely and the dose that should be used in later studies. This early‑stage, Phase I trial will give participants the drug in several treatment cycles lasting a few weeks each, with regular check‑ups to watch for side effects and to see how the cancer responds.

The drug is delivered intravenous, meaning it goes directly into the bloodstream through a small tube placed in a vein. Participants will stay at the clinic for a short period after each infusion while staff monitor vital signs and any possible reactions. Follow‑up visits will include simple scans and blood tests to track tumor size and overall health, and any problems will be recorded and treated according to standard medical guidelines.

The purpose of the trial is to determine whether VQ-101 can slow the progression of this form of Parkinson’s disease compared with placebo. After enrollment, participants will be followed for a period of about one and a half years, during which they will attend regular clinic visits to have their safety checked, report any side effects, and complete simple questionnaires and short tests that evaluate movement, thinking and daily function. Disease changes will be measured using a standard rating tool called the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale, which scores the severity of motor and non‑motor symptoms.

The purpose of the study is to find out whether the spray can improve the sharpness of vision, known as visual acuity, compared with the placebo. Over several months, participants will use the spray daily and attend regular visits where standard eye tests are performed, such as reading letters on a chart, checking the area that can be seen without moving the eyes (visual field), and an eye scan called optical coherence tomography that measures the thickness of retinal layers. The study follows each person from the start of treatment through the end of the observation period to see how vision changes over time.